Vical Inc.
10390 Pacific Center Court
San Diego,
CA 92121-4340
United States - Map
Phone: 858-646-1100
Fax: 858-646-1150
Web Site: http://www.vical.com
| Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It develops DNA-based vaccines and therapeutics for the prevention/treatment of infectious diseases, cardiovascular diseases, and cancer, including Allovectin-7 cancer immunotherapeutic, a Phase III clinical trial product for the treatment of metastatic melanoma; Therapeutic vaccine for cytomegalovirus, a Phase II clinical trial product to prevent viral reactivation and disease after transplant; Prophylactic vaccine for H5N1 pandemic influenza virus, which completed its Phase I clinical trial to protect against infection, disease, and/or viral shedding; Prophylactic vaccine for cytomegalovirus, a preclinical status product, which prevents infection before and during pregnancy to preclude fetal transmission; and Therapeutic vaccine for herpes simplex type 2 virus, a research status product that prevents recurring flare-ups. The company, through corporate collaborations, develops Collategene angiogenic therapy encoding Hepatocyte Growth Factor that induces local growth of blood vessels to restore blood flow to limbs affected by ischemia; Angiogenic therapy encoding Hepatocyte Growth Factor, which completed Phase I clinical trial, induces local growth of blood vessels to restore blood flow to heart affected by ischemia; Apex-IHN prophylactic vaccine that protects farm-raised salmon from infection and disease; and Therapeutic cancer vaccine encoding human tyrosinase, used in adjunct treatment to increase survival time of dogs with oral melanoma. It also has products in Phase I status that treat breast or prostate, colorectal, ovarian, or non-small cell lung cancer; melanoma; or carcinomas of the upper GI tract, colon, kidney, or bladder. Vical Incorporated was founded in 1987 and is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Vijay B. Samant , 56
Chief Exec. Officer, Pres |
N/A
| N/A | Ms. Jill M. Broadfoot , 47
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec. |
N/A
| N/A | Dr. Alain Rolland Pharm.D., Ph.D., 49
Exec. VP of Product Devel. |
N/A
| N/A | Mr. Andrew R. de Guttadauro , 42
VP of Corp. Devel. |
N/A
| N/A | Mr. Kevin R. Bracken , 60
VP of Manufacturing |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
